A B S T R A C T
Most therapeutic attempts to prevent the progression of kidney diseases have been based on interventions to inhibit the production of transforming growth factor-b (TGF-b). Thrombospondins (TSPs) play an important role in activating TGF-b. In the healthy kidney, two TSPs are expressed, TSP1 and TSP2, which exert contrasting effects. While TSP1 is a major activator of TGF-b in renal cells and exerts pro-inflammatory effects both in vitro and in vivo, TSP2 lacks the ability for TGF-b activation but regulates matrix remodeling and inflammation in experimental kidney disease. The effects of TSPs in the kidney have been mostly investigated by using the murine model of unilateral ureteral obstruction. In this model, TSP1 expression is increased along with the development of interstitial fibrosis and TGF-b. Relief of the obstruction gradually improves renal function and decreases the expression in TSP1 and TGF-b1. Several inhibitors of TSP1 prevented progressive interstitial fibrosis in murine models of ureteral obstruction, suggesting that control of latent TGF-b activation by inhibiting TSP1 might represent a novel potential target for preventing renal interstitial fibrosis. However, further studies are needed to assess whether TSP1-mediated TGF-b activation can be safely used in humans. In fact, TSPs normally act to suppress tumors in vivo. Moreover, TGF-b can exert a pivotal function in the immune system, as it may induce the production of regulatory T cells and suppress B cell responses. Knowledge of the molecular mechanisms involved in TGF-b regulation may help in finding effective treatments of tissue fibrosis, cancer and autoimmune disease.
Keywords: angiogenesis, chronic kidney disease, renal interstitial fibrosis, thrombospondin, trasforming growth factor Kidney interstitial fibrosis is a common feature in chronic kidney diseases and is considered to concur with their progression. Interstitial fibrosis is characterized by the accumulation of extracellular matrix in the interstitium associated with tubular atrophy and nephron loss. A number of cell types and molecular pathways have been found to be involved, but the molecular mechanisms of interstitial fibrosis are not fully elucidated. However, there is agreement that transforming growth factor-b (TGF-b) is a central driver of interstitial fibrosis [1] . Conceivably, most therapeutic attempts to prevent the progression of kidney diseases have been based on interventions to inhibit the production of TGF-b. However, while good results have been reported in some (but not all) experimental models, no effective treatment to handle interstitial fibrosis in human kidneys has been found until now. These failures might be related to a too late intervention. It is possible that earlier measures, such as targeting thrombospondins (TSPs) that regulate TGF-b activation and extracellular matrix assembly would be more effective in preventing fibrosis. Furthermore, TSPs may also exert a number of other effects that protect the kidney from progression.
In this minireview, we outline the critical role of TSPs in regulating TGF-b activation and discuss whether manipulation of these proteins could be an alternative approach to modulate the progression of kidney diseases in human beings.
T H E T R A N S F O R M I N G G R O W T H F A C T O R S
There are two types of TGFs, a and b, which are genetically and structurally different and have completely different functions. The polypeptide TGF-a is a member of the epidermal growth factor family, which can initiate cell division during embryogenesis, oncogenesis and angiogenesis [2] .
In contrast, TGF-b is a secreted homodimeric protein that includes three different isoforms (TGF-b1, TGF-b2 and TGFb3). TGF-b belongs to the TGF superfamily of cytokines. It consists of >30 different members and plays an important role in regulating various cellular responses, including cell proliferation and differentiation, extracellular matrix production, immune system, tissue homeostasis and apoptosis. As such, TGF-b is a highly researched cytokine in the fields of cancer and autoimmune diseases, two severe clinical pathologies where TGF-b can exert contrasting effects, as the effects of TGF-b on transcription can be positive or negative depending on the targeted gene and the cellular context [3] . Recently, the attention of nephrologists has been focused on the pathogenic role of TSP type 1 domain-containing 7A (THSD7A) in primary membranous nephropathy (MN). It has been demonstrated that THSD7A is expressed on podocytes of patients with MN and can elicit the production of autoantibodies. The administration of human anti-THSD7A antibodies to mice bound to TSHD7A in podocyte foot processes, induced rearrangement of podocyte cytoskeleton and initiated the histologic lesions of MN. Moreover, anti-THSD7A antibodies were detected in the serum of patients with MN before and after transplantation, suggesting that these antibodies induced a recurrence of MN in the renal transplant [4] .
The TGF-bs are secreted by many inflammatory cell types, like alternatively activated macrophages, in the form of precursor proteins, including the C-terminal pro-region, called latency-associated peptide (LAP), and the N-terminal region, called mature TGF-b or active TGF-b. When secretion of mature TGF-b is associated with that of LAP it cannot interact with its receptor and thus does not elicit any biological effects. Thus these precursor proteins need to be processed intracellularly prior to the release of active TGF-b into the extracellular space. For TGF-b to become biologically active, LAP has either to undergo conformational change or to detach from active TGF-b by serum proteinases like plasmin. TSP1 has a critical role in activating latent TGF-b. This glycoprotein binds to LAP by forming an active ternary LAP-TSP1-TGF-b complex and mediates a conformational change within this complex, abolishing the specific interactions required for TGF-b latency. The other mechanism of TGF-b activation involves the release of mature TGF-b from this complex, a reaction catalyzed by serum proteinases on the surface of macrophages where the latent TGF-b complex is bound to CD36 via its ligand TSP1. Either of these modifications of the latent LAP-TGF-b complex exposes the TGF-b receptor binding site. At the cell surface, the TGF-b complex consists of two type I and two type II transmembrane receptors (TbRI and TbRII, respectively), which have serine/ threonine kinase activity [4, 5] . The type I receptors are signal propagating, whereas two type II receptors are activating components [6] .
T G F -b S I G N A L I N G C A S C A D E
The TGF-b superfamily has several types of ligands. Signaling begins with the binding of a TGF-b ligand to a specific type II receptor, which is an active kinase. This binding causes rotation of the receptor with rearrangement of cytoplasmic kinase domains in a catalytically favorable orientation. Type II receptor dimers catalyze the phosphorylation of the type I receptor serine residues, which activates the protein to propagate the signal to downstream substrates [7] . In turn, activation of TGF-b receptors induces signaling via phosphorylation and formation of small mother against decapentaplegic (Smad) complexes that are translocated to the nucleus, where they act as transcription factors in association with DNA-binding partner proteins [8] . This Smad-dependent 'canonical' signaling is the best studied signaling pathway of TGF-b, but a Smad-independent 'non-canonical' signaling pathway operates in a number of diverse biological processes [9] .
Smads are a family of intracellular signal transducer proteins that includes eight members. Smads 1, 2, 3, 5 and 8 are called receptor-regulated Smads (R-Smads), containing the C-terminal Ser-X-Ser motif for phosphorylation by the type I receptors. Smad4 (co-Smad) interacts with R-Smads to participate in the signal, but Smad6 and Smad7 (I-Smads) inhibit the activation of R-Smads and co-SMAD. After activation, TGF-b recruits and phosphorylates the R-Smads, generally Smad2 and Smad3, which then form trimeric complexes with the co-Smad4 for subsequent nuclear transcriptional regulation in partnership with various DNA binding cofactors. Target genes that regulate cell homeostasis include Smad7, which provides a universal feedback loop for negative regulation of this pathway. Indeed, Smad7 inactivates transcription by binding with R-Smads or a co-Smad [10] . Smad signaling represents the dominant pathway of TGF-b signaling in progressive renal fibrosis. TGF-b1/Smads signaling (i) influences the recruitment and activation of macrophages, T cells and mast cells; (ii) can induce apoptosis of endothelial cells and podocytes; (iii) can favor proliferation of fibroblasts and mesangial cells and (iv) can induce myofibroblast proliferation and production of extracellular matrix by inducing transcription of collagen genes and inhibiting matrix metalloproteinases genes [11, 12] . However, since Smads bind directly to a number of microRNAs, they either negatively or positively regulate their expression and function in renal fibrosis [13] [14] [15] . Signaling specificity is determined by the choice of type I and II receptors that each particular TGF-b family member can bind and drive into a complex. With some notable exceptions, the receptors for TGF-b signal through Smad2 and Smad3 [16, 17] . In the context of renal fibrosis, Smad3 is pathogenic, whereas Smad2 and Smad7 are protective since they can control and inhibit the expression of Smad3, respectively [18] . Smad3 mediates renal fibrosis by upregulating miR-21 and miR-192, while downregulating miR29 and miR200 families [19] . Of interest, the downregulation of miR29 can result in an increased expression of a disintegrin and metalloprotease with a [20] . It was recently demonstrated that the activity of ADAMTS 2, 3 and 14 can regulate matrix deposition and remodeling at multiple levels [21] .
T H R O M B O S P O N D I N S
TSPs are highly expressed during embryonic stages. Their levels decrease with age but TSPs can be re-expressed in response to different types of injury. Extracellular TSPs have a critical role in activating TGF-b. These calcium-binding glycoproteins are involved in the regulation of angiogenesis, proliferation, apoptosis, the NO-cGMP-dependent protein kinase pathway and TGF-b activation. The majority of these functions involve the regulation of cellular phenotype through interaction with various cell surface proteins and activation of their downstream signaling pathways, thus TSPs are considered matrix cellular proteins [22] . Mammals encode five TSPs in two structural subgroups, i.e. A (containing TSP1 and TSP2) and B (containing TSP3, TSP4 and TSP5). In the healthy kidney, only TSP1 and TSP2 are expressed at low levels, but both can be upregulated during disease [23] . Both TSP1 and TSP2 are tightly regulated by different cytokines, receptors and proteases. Together with other matrix molecules they modulate the organization of collagen fibrils and growth factors, including TGF-b. However, TSPs may exert contrasting effects in the kidney.
TSP1
Most of the available studies have focused on TSP1, the first member of the TSP family that was identified on activated platelets [24] . As pointed out before, TSP1 is a major activator of latent TGF-b, either by mediating a conformational change of the complex LAP-TSP1-TGF-b or by binding the TGF-b complex to CD36 on the surface of macrophages favoring the release of active TGF-b by plasmin. The effects of TSP1 mainly depend on the local environment and on their interactions with at least 12 cell adhesion receptors, including CD36, CD47, heparin sulphate, calreticulin, low-density lipoprotein-related protein and avb3 integrin, as well as specific peptide sequences such the TGF-b-activating sequence of RFK peptide [25] . In the kidney, TSP1 is a major activator of TGF-b in renal cells and exerts proinflammatory effects both in vitro and in vivo.
The effects of TSP1 in the kidney have been mostly investigated by using the model of unilateral ureteral obstruction in the rat. This well-established in vivo model of progressive interstitial fibrosis is associated with elevated levels of TGF-b in the obstructed kidney [26, 27] . Several mechanisms activate profibrotic signaling pathways in this model, but recent reports have pointed out the critical role of TSP1. In rats with unilateral ureteral obstruction, TSP1 expression was increased along with the development of interstitial fibrosis, collagen III and TGF-b. Relief of the obstruction produced a gradual improvement in renal function and decreased expression in TSP1, TGF-b1 and collagen III. Mice deficient in TSP1 displayed less inflammation and had better preservation of renal tissue and the peritubular capillary network as compared with wild-type mice [28] .
Inhibitors of TSP1 also prevented progressive interstitial fibrosis and tubular atrophy in murine models of ureteral obstruction. For example, LSKL, a small molecular peptide antagonist of TSP1, attenuated interstitial fibrosis by preventing TSP1-mediated activation of TGF-b1. In rats subjected to unilateral ureteral obstruction, severe tubular dilatation and atrophy, interstitial inflammation and collagen accumulation developed after surgery. LSKL significantly inhibited interstitial fibrosis, including tubular injury, as well as collagen deposition in comparison with untreated controls. The protein and mRNA levels of TSP1 increased notably after surgery in controls while they significantly decreased in LSKL-treated rats [29] . In addition, ginsenosides are a class of natural product steroid glycosides found almost exclusively in the plant ginseng. In a rat model of ureteral obstruction, ginsenoside Rg1 inhibited renal interstitial fibrosis by suppressing the expression of TSP1 [30] . A short hairpin RNA vector designated Thbs-1, significantly suppressed TSP1 in both transcriptional and translational levels in in vitro cultured cells and in vivo kidney fibrosis induced by unilateral ureteral obstruction in mice [31] .
Inhibiting TSP1 production proved to be successful also in other models of kidney interstitial fibrosis. For example, angiotensin II and high glucose stimulated increases in TSP1 protein levels and increased TGF-b activity in the conditioned media of rat mesangial cells. Peptide antagonists of TSP1 blocked angiotensin II and glucose-induced TGF-b activation [32] . In another study, Wistar rats were randomly divided into three groups: control, induced type II diabetes mellitus and diabetes treated with valsartan. As compared with controls, diabetic aortas showed reduced distensibility and compliance, with excessive deposition of extracellular matrix. Components in the TSP1-mediated TGF-b1/Smads signaling pathway, including TSP1, TGF-b1, TGF-b type II receptor, Smad2 and Smad3, were accumulated in vascular smooth muscle cytoplasm of diabetic aortas and their protein and mRNA levels were upregulated. All these abnormalities were attenuated by valsartan [33] . These data suggest that in diabetic patients and in patients affected by severe arterial hypertension, glucose control and angiotensin receptor blockers could prevent the cascade of TGF-b initiated by TSP1 and may protect from progression of kidney disease.
Independent of activation of TGF-b, TSP1 may protect from podocyte injury. In patients with primary focal and segmental glomerular sclerosis, injured podocytes express more TSP1 [34] . In adriamycin-treated mice, TSP1 increased podocyte apoptosis and actin cytoskeleton disorganization. This effect of TSP1 was mediated by a CD36-dependent mechanism and involved stimulation of the p38 mitogen-activated protein kinase pathway. In vivo data demonstrated that TSP1 deficiency protected mice from adriamycin-induced podocyte loss and foot process effacement, suggesting a protective role of TSP1 antagonists in proteinuric diseases [35] .
TSP2
Unlike TSP1, TSP2 is produced by fibroblasts and smooth muscle cells. Studies in the mouse have shown that TSP2 is a close relative of TSP1 but differs in its temporal and spatial distribution. TSP2 is not an integral component of fibrils and does
not contribute directly to the structural integrity of connective tissue elements. Rather, it operates at a distance by modulating the activity of growth factors in the pericellular environment and by favoring matricellular angiogenesis [36] . While TSP2 lacks the ability for TGF-b activation, it regulates extracellular matrix remodeling and inflammation in experimental kidney disease [37] . TSP2 might be a potential therapeutic agent to inhibit TGF-b activation and extracellular matrix accumulation. In a murine model of anti-Thy1 mesangial proliferative glomerulonephritis, muscular overexpression of TSP2 reduced glomerular TGF-b activation and glomerular extracellular matrix formation and inhibited both glomerular endothelial and mesangial cell proliferation. The inflammatory response, as monitored by T cells and antigen-presenting cells, was reduced significantly by TSP2 overexpression [38] . TSP2 might also exert an unfavorable impact on kidney disease by increasing thrombogenesis. In TSP2 knockout mice, reduced accumulation of extracellular matrix and von Willebrand factor were observed, showing that TSP2 may increase the thrombogenic response by mediating extracellular matrix assembling [39] . On the other hand, despite its anti-inflammatory and TGF-b activation blocking effects, TSP2 gene therapy did not ameliorate, but rather worsened, experimental chronic allograft nephropathy. This effect was most likely due to its antiangiogenic properties on the renal microvasculature. Compared with controls, TSP2-treated rats showed significantly higher glomerular and peritubular endothelial rarefaction and reduced endothelial cell proliferation in transplanted kidneys, associated with decreased levels of renal vascular endothelial growth factors [40] .
C O N C L U S I O N S
Control of latent TGF-b activation by inhibiting TSP1 might represent a novel potential target for preventing renal interstitial fibrosis and progression of chronic kidney disease. However, further studies are needed to assess whether inhibition of TSP1-mediated TGF-b activation can be effective and relatively safe in managing inflammatory renal diseases in humans. This question is of critical importance since TSP1 and TSP2 are generally present in tumor microenvironments and can play an important role in regulating apoptosis and angiogenesis of cancer cells. Although some studies have shown that TSP can favor cancer progression [41] , the majority of reports indicate that endogenous TSP1 normally acts to suppress tumors in vivo. These contradictory results suggest that the biological activities of TSP1 could depend on the conformation and concentration of TSP1. The anti-oncogenic activity of TSP1 can be attributed to several recognition motifs. It relates to its capacity to trigger programmed cell death upon ligation of the CD47 receptor [42] and to inhibit vascular endothelial growth factor A by its interaction with CD36 [43] . Also, TSP2 has been shown to inhibit tumor growth and angiogenesis better than TSP1, by binding to CD36 [44] . Characterization of these motifs has led to the use of recombinant proteins containing these motifs, including fragments of TSP1 or human TSP2 [45, 46] . It should also be taken into account that TGF-b can exert a pivotal function in the immune system, as it may induce the production of regulatory T cells [47, 48] and suppress B cell responses [49] . The possibility of using TGF-b as a therapeutic agent is going to be explored in some preliminary clinical studies in autoimmune diseases. Because of the role of TGF-b in maintaining immune homeostasis [50], one should consider that its inhibition might promote tissue inflammation and autoimmunity.
These apparent discrepancies in the functions of TSPs and TGF-b can be explained by the need of the human body to regulate biological events by homeostatic mechanisms. Many diseases result from the failure of one or more homeostatic mechanisms. A deeper knowledge of the molecular mechanisms involved in TGF-b regulation may help in finding effective treatments for tissue fibrosis, cancer and autoimmune disease. 
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